Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $47.5400 (0.11%) ($46.8100 - $48.4600) on Thu. Feb. 9, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.85% (three month average) | RSI | 27 | Latest Price | $47.5400(0.11%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -2.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(45%) XBI(44%) IWO(41%) IWC(37%) IWM(37%) | Factors Impacting SAGE price | SAGE will decline at least -1.425% in a week (0% probabilities). VIXM(-12%) UUP(-9%) TLT(-8%) SHY(-4%) IGOV(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.425% (StdDev 2.85%) | Hourly BBV | 0 () | Intraday Trend | -0.1% | | | |
|
Resistance Level | $49.73 | 5 Day Moving Average | $47.67(-0.27%) | 10 Day Moving Average | $47.48(0.13%) | 20 Day Moving Average | $49.73(-4.4%) | To recent high | -14.6% | To recent low | 3.3% | Market Cap | $2.469b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |